DAFTAR PUSTAKA

1. Kementerian Kesehatan RI. Stop kanker. Pusat data dan informasi

kementerian kesehatan RI. Jakarta: Kementerian Kesehatan; 2015.
2. Christanti J, Prasetyo A. Tingkat ketahanan hidup penderita kanker nasofaring
pada berbagai modalitas terapi studi kasus yang menjalani terapi konvensional
dan pengobatan komplementer alternatif. M Med Indones. 2012;46(2):138-46
3. Morrissey KM, Yuraszeck TM, Li CC, Zhang Y, Kasichayanula S.
Immunotherapy and novel combinations in oncology: Current landscape,
challenges, andopportunities. Clin Transl Sci. 2016;9:89-104.
4. Li YS, Li FF, Jiang F, Lv XQ, Zhang RJ, Lu AP, et al. A mini-review for
cancer immunotherapy: Molecular understanding of PD-1/PD-L1 pathway &
translational blockade of immune checkpoints. Int J Mol Sci. 2016;17:1151.
5. Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy:
Harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436-43.
6. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S.
Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012;62:309-35.
7. Jiang T, Zhou CC. The past, present and future of immunotherapy against
tumor. Transl Lung Cancer Res. 2015;4(3):253-64.
8. Parish CR. Cancer immunotherapy: The past, the present and the future.
Immunology and Cell Biology 2003;81:106-13
9. Meiliana A, Dewi NM, Wijaya A. Cancer immunotherapy: A review. Indones
Biomed J. 2016;8(1):1-20.
10. Ferlay, J., Soerjomataram, I., Ervik, M., Forman, D., Bray, F., Dikshit, R., ...
Parkin, D.M. (2014). Globocan 2012: Estimated Cancer Incidance, Mortality
and Prevalence Worldwide in 2012. Retrived from
http://globocan.iarc.fr/Pages/fact_she ets_population.aspx.
11. Kashani, F. L., Vaziri, S., Akbari, M. E., Jamshidifar, Z., & Sanaei, H. (2014).
Stress Coping Skills Training and Distress in Women with Breast Cancer.
Procedia - Social and Behavioral Sciences, 159, 192–196.
http://doi.org/10.1016/j.sbspro.2014.1 2.355.
12. Sunaryati SS. 2011. 14 Penyakit Paling Sering Menyerang dan Mematikan.
Jogjakarta: Flash Books
13. Price, A.S., Wilson, M.L. 2006. Patofisiologi Konsep Klinis Proses-Proses
Penyakit. Alih Bahasa: dr. Brahm U. Jakarta: Penerbit Buku KedokteranEG
14. Rasjidi, Imam. 2009. Manual Seksio Sesarea & Laparotomi Kelainan
Adneksa.Jakarta : CV Sagung Seto.
15. America Caner Socciety (ACS) What is breast Cancer. 2011.
16. Prat J, Gallardo A, Cuatrecass M, Catasus L. Endometrial carcinoma;
pathology and genetics. Pathology 2007;39(1):72-87
17. Heffner LJ, Schust DJ. At a glance system reproduksi. Edisi ke-2. Jakarta :
Erlangga.2006.h.90-1.
18. Yotnda Patricia. Immunotherapy of cancer. 1st ed. Humana Press; 2010.
19. Restifo NP, Robbins PF, Rosenberg SA. Principles of immunotherapy.
Dalam: DeVita, Vincent T, Lawrence, Theodore S, Rosenberg S, editor.
Devita, Hellman & Rosenberg’s cancer: principles and practice of oncology.
8th ed, Philladelphia: Lippincot Williams & Wilkins; 2008.
20. Jacqueline Stanley, Reginald Gorczynsk. Essential immunobiological
concepts in clinical immunology. Dalam: Vademecum, Austin. Clinical
immunology. Texas: Landes Bioscience; 1999.
21. I Dewa Gede Sukardja. Onkologi klinik. Edisi ke-2. Surabaya : Airlangga
University Press; 2000
22. DunnGP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu
Rev Immunol. 2004;22:329–60. Excellent review on immunologic cancer
surveillance and immune-editing
23. Vesely MD, et al. Natural innate and adaptivy immunity to cancer. Annu Rev
Immunol. 2011;29:235–71.
24. Hamanishi J, et al. Safety and antitumor activity of anti-PD-1 antibody,
nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol.
2015;33(34):4015–22. First published report of a checkpoint inhibitor in
ovarian cancer
25. Disis ML, PatelMR, Pant S, Hamilton EP, Lockhart AC. Avelumab
(MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian
cancer from the JAVELIN Solid Tumor phase Ib trial: safety and clinical
activity. J Clin Oncol. 2016;35(suppl; abstr 5533).
26. Varga A, Piha-Paul SA, Ott PA, Mehnert JM, Berton- Rigaud D, Johnson EA,
Cheng JD, Yuan S, Rubin EH, Mate DE. Antitumor activity and safety of
pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian
cancer: interim results from a phase Ib study. J Clin Oncol. 2015;33(suppl;
abstr 5510).
27. Diefenbach CS, et al. Safety and immunogenicity study of NY-ESO-1b
peptide and montanide ISA-51 vaccination of patients with epithelial ovarian
cancer in high-risk first remission. Clin Cancer Res. 2008;14(9):2740–8
28. Janelle B. Pakish, MD, MSAmir A. Jazaeri, MD. Immunotherapy in
Gynecologic Cancers: Are We There Yet?. Curr. Treat. Options in Oncol.
(2017) 18:59 DOI 10.1007/s11864-017-0504-y
29. Frenel JS, Le Tourneau C, O'Neil BH, Ott PA, Piha-Paul SA.
Pembrozlizumab in patients with advanced cervical sqaumous cell cancer:
preliminary results from the phase Ib KEYNOTE-028 study. J ClinOncol.
2016;34(suppl; abstr 5515).
30. Schellens JHM,Marabelle A, Zeigenfuss S, Ding J, Pruitt SK, Chung HC.
Pembrolizumab for previously treated advanced cervical squamous cell
cancer: preliminary results from teh phase 2 KEYNOTE-158 study. J Clin
Oncol. 2017;35(suppl; abstr 5514).
31. Delord JP, Hollebecque A, De Boer JP, De Greve J, Machiels JPH, Leidner
RS, Ferris RL, Roa S, Soumaoro I, Cao ZA, Kang H, Topalian SL. An open-
label, multicohort, phase I/II study to evaluate nivolumab in patients with
virus-associated tumors (CheckMate 358): efficacy and safety in recurren or
metastatic (R/M) nasopharyngeal carcinoma (NPC). J ClinOncol.
2017;35(suppl; abstr 6025).
32. Paraghamian SE, Longoria TC, Eskander RN. Metastatic small cell
neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor,
nivolumab: a case report. Gynecol Oncol Res Pract. 2017;4:3.
33. Dellinger TH, Monk BJ. Systemic therapy for recurrent endometrial cancer: a
review of North American trials. Expert Rev Anticancer Ther. 2009;9(7):905–
16.
34. Dizon DS. Treatment options for advanced endometrial carcinoma. Gynecol
Oncol. 2010;117(2):373–81
35. Alexandrov LB, et al. Signatures of mutational processes in human cancer.
Nature. 2013;500(7463):415– 21.
36. Frequently cited reference on tumor classification by number of somatic
mutation
37. Howitt BE, et al. Association of polymerase e–mutated and microsatellite-
instable endometrial cancers with neoantigen load, number of tumor-
infiltrating lymphocytes, and expression of pd-1 and pd-l1. JAMA Oncology.
2015;
38. Le DT, et al. PD-1 blockade in tumors with mismatchrepair deficiency.NEngl
JMed. 2015;372(26):2509–20.
39. Ott PA, et al. Safety and antitumor activity of pembrolizumab in advanced
programmed death ligand 1-positive endometrial cancer: results from
theKEYNOTE-028 study. J Clin Oncol. 2017;35(22):2535–41.